My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 293

    1.

    Regulation of glucose transport and insulin signaling by troglitazone or metformin in adipose tissue of type 2 diabetic subjects.

    Ciaraldi TP, Kong AP, Chu NV, Kim DD, Baxi S, Loviscach M, Plodkowski R, Reitz R, Caulfield M, Mudaliar S, Henry RR.

    Diabetes. 2002 Jan;51(1):30-6.PMID: 11756319 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy.

    Phillips SA, Ciaraldi TP, Kong AP, Bandukwala R, Aroda V, Carter L, Baxi S, Mudaliar SR, Henry RR.

    Diabetes. 2003 Mar;52(3):667-74.PMID: 12606507 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjects.

    Kim YB, Ciaraldi TP, Kong A, Kim D, Chu N, Mohideen P, Mudaliar S, Henry RR, Kahn BB.

    Diabetes. 2002 Feb;51(2):443-8.PMID: 11812753 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients.

    Yu JG, Kruszynska YT, Mulford MI, Olefsky JM.

    Diabetes. 1999 Dec;48(12):2414-21.PMID: 10580431 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Regulation of skeletal muscle morphology in type 2 diabetic subjects by troglitazone and metformin: relationship to glucose disposal.

    Mathieu-Costello O, Kong A, Ciaraldi TP, Cui L, Ju Y, Chu N, Kim D, Mudaliar S, Henry RR.

    Metabolism. 2003 May;52(5):540-6.PMID: 12759881 [PubMed - indexed for MEDLINE]Related articles

    6.

    Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.

    Chu NV, Kong AP, Kim DD, Armstrong D, Baxi S, Deutsch R, Caulfield M, Mudaliar SR, Reitz R, Henry RR, Reaven PD.

    Diabetes Care. 2002 Mar;25(3):542-9. Erratum in: Diabetes Care 2002 May;25(5):947. PMID: 11874944 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes.

    Strowig SM, Avilés-Santa ML, Raskin P.

    Diabetes Care. 2002 Oct;25(10):1691-8.PMID: 12351463 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects.

    Virtanen KA, Hällsten K, Parkkola R, Janatuinen T, Lönnqvist F, Viljanen T, Rönnemaa T, Knuuti J, Huupponen R, Lönnroth P, Nuutila P.

    Diabetes. 2003 Feb;52(2):283-90.PMID: 12540598 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Effect of troglitazone on body fat distribution in type 2 diabetic patients.

    Mori Y, Murakawa Y, Okada K, Horikoshi H, Yokoyama J, Tajima N, Ikeda Y.

    Diabetes Care. 1999 Jun;22(6):908-12.PMID: 10372240 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.

    Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, Shulman GI.

    N Engl J Med. 1998 Mar 26;338(13):867-72.PMID: 9516221 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Decrease in serum C-reactive protein levels by troglitazone is associated with pretreatment insulin resistance, but independent of its effect on glycemia, in type 2 diabetic subjects.

    Yatagai T, Nakamura T, Nagasaka S, Kusaka I, Ishikawa SE, Yoshitaka A, Ishibashi S.

    Diabetes Res Clin Pract. 2004 Jan;63(1):19-26.PMID: 14693409 [PubMed - indexed for MEDLINE]Related articles

    12.

    Troglitazone and metformin, but not glibenclamide, decrease blood pressure in Otsuka Long Evans Tokushima Fatty rats.

    Kosegawa I, Chen S, Awata T, Negishi K, Katayama S.

    Clin Exp Hypertens. 1999 Apr;21(3):199-211.PMID: 10225476 [PubMed - indexed for MEDLINE]Related articles

    13.

    Troglitazone improves GLUT4 expression in adipose tissue in an animal model of obese type 2 diabetes mellitus.

    Furuta M, Yano Y, Gabazza EC, Araki-Sasaki R, Tanaka T, Katsuki A, Hori Y, Nakatani K, Sumida Y, Adachi Y.

    Diabetes Res Clin Pract. 2002 Jun;56(3):159-71.PMID: 11947963 [PubMed - indexed for MEDLINE]Related articles

    14.

    Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.

    Kruszynska YT, Yu JG, Olefsky JM, Sobel BE.

    Diabetes. 2000 Apr;49(4):633-9.PMID: 10871202 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Tissue-specific expression and regulation of GSK-3 in human skeletal muscle and adipose tissue.

    Ciaraldi TP, Oh DK, Christiansen L, Nikoulina SE, Kong AP, Baxi S, Mudaliar S, Henry RR.

    Am J Physiol Endocrinol Metab. 2006 Nov;291(5):E891-8. Epub 2006 Jun 6.PMID: 16757548 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Efficacy of troglitazone on body fat distribution in type 2 diabetes.

    Akazawa S, Sun F, Ito M, Kawasaki E, Eguchi K.

    Diabetes Care. 2000 Aug;23(8):1067-71.PMID: 10937499 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Primary, secondary, tertiary, and quaternary treatment with troglitazone in type 2 diabetes mellitus in an outpatient clinical practice.

    Hershon KS, Hershon PM.

    Endocr Pract. 2000 Jan-Feb;6(1):20-5.PMID: 11419922 [PubMed - indexed for MEDLINE]Related articles

    18.

    Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects.

    Frias JP, Yu JG, Kruszynska YT, Olefsky JM.

    Diabetes Care. 2000 Jan;23(1):64-9.PMID: 10857970 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Troglitazone improves whole-body insulin resistance and skeletal muscle glucose use in type II diabetic patients.

    Yokoyama I, Yonekura K, Moritan T, Tateno M, Momose T, Ohtomo K, Inoue Y, Nagai R.

    J Nucl Med. 2001 Jul;42(7):1005-10.PMID: 11438619 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Troglitazone add-on therapy to a combination of sulfonylureas plus metformin achieved and sustained effective diabetes control.

    Gavin LA, Barth J, Arnold D, Shaw R.

    Endocr Pract. 2000 Jul-Aug;6(4):305-10.PMID: 11242607 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity